Philippe Saiag
Expertise in
5
conditions

Philippe Saiag

Boulogne-billancourt, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
Boulogne-billancourt, FR 

Overview

Philippe Saiag practices in Boulogne-billancourt, France. Mr. Saiag is highly rated in 5 conditions, according to our data. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Neuroendocrine Tumor, and Basal Cell Skin Cancer.

His clinical research consists of co-authoring 162 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Boulogne-billancourt, France
Other Locations
Avenue de la République
Tours, 37170, France
Paris, 92104, France
Versailles, France
Besancon, France
Neuilly-sur-seine, France
Villejuif, France
Bordeaux, France
104 Boulevard R. Poincaré, Saint-quentin-le-verger, 92380, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Constitution of a National Cohort of Patients With Metastatic Melanoma Resectable Stage II or Stage III or IV or Unresectable Primary With the Objective of Setting up Epidemiological Monitoring and Clinico-biological Database, MELBASE
Constitution of a National Cohort of Patients With Metastatic Melanoma Resectable Stage II or Stage III or IV or Unresectable Primary With the Objective of Setting up Epidemiological Monitoring and Clinico-biological Database, MELBASE
Enrollment Status: Recruiting
Publish Date: February 11, 2025
Intervention Type: Other
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Nivolumab + Ipilimumab, Encorafenib + Binimetinib
Study Phase: Phase 2
Nivolumab in Combination With High Dose Radiotherapy at Varied Tumor Sites in Advanced Melanoma and no Prior Antitumoral Treatment
Nivolumab in Combination With High Dose Radiotherapy at Varied Tumor Sites in Advanced Melanoma and no Prior Antitumoral Treatment
Enrollment Status: Completed
Publish Date: November 15, 2023
Intervention Type: Radiation, Biological
Study Drug: Nivolumab
Study Phase: Phase 2
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Enrollment Status: Completed
Publish Date: December 06, 2022
Intervention Type: Drug
Study Drugs: Imiquimod Cream+Surgery, Surgery
Study Phase: Phase 3
Evaluation of Cobimetinib + Vemurafenib Combination Treatment in Patients With Brain Metastasis BRAFV600 Mutated Cutaneous Melanoma
Evaluation of Cobimetinib + Vemurafenib Combination Treatment in Patients With Brain Metastasis BRAFV600 Mutated Cutaneous Melanoma
Enrollment Status: Completed
Publish Date: January 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Enrollment Status: Unknown
Publish Date: March 04, 2019
Intervention Type: Biological
Study Drug: PEG IFN Alfa-2b
Study Phase: Phase 3
View 5 Less Clinical Trials

162 Total Publications

Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study.
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study.
Journal: Journal for immunotherapy of cancer
Published: February 23, 2026

Frequently Asked Questions about Philippe Saiag

Is Philippe Saiag a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Philippe Saiag is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Philippe Saiag participate in research or clinical trials?

Yes. Philippe Saiag has published 162 articles and abstracts on conditions like Melanoma. You can view a list of Philippe Saiag's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Saiag's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile